MedTrace Logo

A Prospective Epidemiological Cohort Study Evaluating Occurrences of Influenza-like Illness.

NCT05184387 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 66

Last updated 2022-07-19

No results posted yet for this study

Summary

This Prospective epidemiological cohort study is being conducted in order to generate epidemiological data in support of Osivax's clinical development of a broad spectrum influenza vaccine based upon the internal influenza nucleoprotein (NP) as a target for immune response.

Conditions

Interventions

OTHER

Blood samples

Collection of blood samples and completion of an electronic Diary (eDiary)

Sponsors & Collaborators

  • Center for vaccinology (CEVAC), University of Ghent, Belgium

    collaborator UNKNOWN

  • Osivax

    lead INDUSTRY

Principal Investigators

  • Isabel Leroux-Roels, MD, PhD · Centre for Vaccinology (CEVAC), Ghent University Hospital

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2022-07-12
Completion
2022-07-12

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05184387 on ClinicalTrials.gov